Published in BMJ Case Rep on August 17, 2011
Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol (1995) 5.51
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med (2004) 4.05
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood (2006) 2.97
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood (1992) 2.81
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica (2007) 2.44
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2006) 1.94
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood (2007) 1.83
Autologous stem cell transplantation for primary systemic amyloidosis. Blood (2002) 1.58
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood (1998) 1.48
AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid (2002) 1.44
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood (1996) 1.42
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood (2010) 1.34
An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant (2001) 1.20
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol (1998) 1.12
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol (2010) 1.04
An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid (2007) 1.00
Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant (2007) 0.95
Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol (2011) 0.93
Current concepts on the pathogenesis of systemic amyloidosis. Nephrol Dial Transplant (1996) 0.88
Primary AL-amyloidosis, ulcerative colitis and collagenous colitis in a 57-year-old woman: a case study. Scand J Gastroenterol (2004) 0.81
Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant (2000) 0.81
High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood (1996) 0.79
High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int (2003) 0.79
Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis. Intern Med (2007) 0.77
Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med (2003) 0.77
Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Wien Klin Wochenschr (2006) 0.77
Regression of cardiac amyloid after autologous stem-cell transplantation. J Heart Lung Transplant (2009) 0.77
Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant (2006) 0.76
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med (2010) 2.11
Naïve T cells correlate with mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol (2013) 2.03
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica (2006) 1.64
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma (2006) 1.52
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood (2005) 1.44
The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood (2007) 1.35
Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood (2002) 1.22
Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res (2005) 0.90
Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol (2002) 0.88
Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome. Am J Hematol (2012) 0.88
Patients' perceptions of having a central venous catheter or a totally implantable subcutaneous port system-results from a randomised study in acute leukaemia. Support Care Cancer (2008) 0.86
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. Hematol J (2004) 0.86
Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution. Ups J Med Sci (2012) 0.86
Totally implantable subcutaneous port system versus central venous catheter placed before induction chemotherapy in patients with acute leukaemia-a randomized study. Support Care Cancer (2003) 0.85
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol (2002) 0.85
HLA-DR(hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD. Clin Transl Gastroenterol (2012) 0.85
A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis (2004) 0.84
[Aquagenic pruritus from polycythaemia vera--treatment with paroxetine, a selective serotonin reuptake inhibitor]. Ugeskr Laeger (2008) 0.81
Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course. Eur J Haematol (2002) 0.81
Fluorescence in situ hybridization for the study of cell lineage involvement in myelodysplastic syndromes with chromosome 5 anomalies. Cancer Genet Cytogenet (2002) 0.80
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up. Acta Haematol (2005) 0.76
Naïve T cells in the gut: how to really find them? Scand J Gastroenterol (2014) 0.75